ArticleScientific reports2020
Streptomyces sp SM01 isolated from Indian soil produces a novel antibiotic picolinamycin effective against multi drug resistant bacterial strains.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 68 citations in OpenAlex.
- An indole dimer antifungal metabolite from a rice seed endophyte inhibits ergosterol biosynthesis in fungal pathogens.Applied and environmental microbiology · 2026Article
- Genomic insights and biosynthetic gene cluster analysis ofMicrobiology spectrum · 2026Article
- SEOH, a novel marine-derived spirostenoid: potent broad-spectrum antimicrobial activity against multidrug-resistant aquaculture pathogens.Applied microbiology and biotechnology · 2025Article
- Review
- Article
- Metabolic engineering approaches for the biosynthesis of antibiotics.Microbial cell factories · 2025Review
- Actinobacteria: Smart Micro-Factories for The Health Sector.Recent patents on biotechnology · 2025Review
- Exploring the diversity and antimicrobial potential of actinomycetes isolated from different environments in Saudi Arabia: a systematic review.Frontiers in microbiology · 2025Review
- Exploring northeast India's culturable soil Actinomycetia for potent antibacterial agents against gram-positive bacterial pathogens of clinical importance.Scientific reports · 2024Article
- Isolation, Antibacterial Activity and Molecular Identification of Avocado Rhizosphere Actinobacteria as Potential Biocontrol Agents ofMicroorganisms · 2024Article
- Metabolic Comparison and Molecular Networking of Antimicrobials inInternational journal of molecular sciences · 2024Article
- Diversity, molecular phylogenetics, and antibiotic biosynthetic potential of endophytic Actinobacteria isolated from medicinal plants in Nigeria.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Article
- Draft genome sequence of probiotic bacteriumMicrobiology resource announcements · 2023Article
- Bioactive Metabolites from Terrestrial and Marine Actinomycetes.Molecules (Basel, Switzerland) · 2023Review
- Isolation and Identification of Bioactive Compounds fromAntibiotics (Basel, Switzerland) · 2022Article
- Exploring the Plant Growth-Promotion of FourPlants (Basel, Switzerland) · 2022Article
- Streptomyces pimonensis sp. nov., isolated from the Taklimakan desert in Xinjiang, China.Archives of microbiology · 2022Article
- An antibacterial compound pyrimidomycin produced by Streptomyces sp. PSAA01 isolated from soil of Eastern Himalayan foothill.Scientific reports · 2022Article
- Production and characterization of a broad-spectrum antimicrobial 5-butyl-2-pyridine carboxylic acid from Aspergillus fumigatus nHF-01.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A Kashmir Himalayan (India) soil isolate, Streptomyces sp. SM01 was subjected to small scale fermentation for the production of novel antimicrobials, picolinamycin (SM1). The production has been optimized which found to be maximum while incubated in AIA medium (pH 7) for 7 days at 30 °C. Seven days grew crude cell-free culture media (50 µL) showed a larger zone of inhibition against Staphylococcus aureus compared to streptomycin (5 µg) and ampicillin (5 µg). Extraction, purification, and chemical analysis of the antimicrobial component has been proved to be a new class of antibiotic with 1013 dalton molecular weight. We have named this new antibiotic as picolinamycin for consisting picolinamide moiety in the center of the molecule and produced by a Streptomyces sp. In general, the antimicrobial potency of this newly characterized antibiotic found to be higher against Gram-positive organisms than the tested Gram-negative organisms. The MIC of this antimicrobial compound was found to be 0.01 µg/ml for tested Gram-positive organisms and 0.02 to 5.12 µg/ml for Gram-negative organisms. Furthermore, it showed strong growth impairments of several multidrug resistance (MDR) strains, including methicillin-resistant strains of Staphylococci and Enterococci with the MIC value of 0.04 to 5.12 µg/ml and MDR (but methicillin-sensitive) strains of S. aureus with the MIC value of 0.084 µg/ml. It also showed anti-mycobacterial potential in higher concentrations (MIC is 10.24 µg/ml). Picolinamycin however did not show toxicity against tested A549 human cell line indicating that the spectrum of its activity limited within bacteria only.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.